Characterization of the emerging HIV type 1 and HCV epidemics among injecting drug users in Dushanbe, Tajikistan.
This study aimed to determine HIV, HCV, and syphilis prevalence and correlates, and to characterize the molecular epidemiology of HIV-1 among injecting drug users (IDUs) in Dushanbe, Tajikistan. A cross-sectional study assessing risk factors for HIV and HCV through an interview administered survey was conducted. A total of 491 active adult IDUs were recruited from May to November 2004 in Dushanbe, Tajikistan. HIV-1 antibody status was determined with rapid testing and confirmed with ELISA. HCV antibody testing was conducted using a BIOELISA HCV kit. HIV-1 subtyping was done on a subset with full-length sequencing. Correlates of HIV and HCV infection were assessed using logistic regression. Overall prevalence of HIV was 12.1%, HCV was 61.3%, and syphilis was 15.7%. In a multivariate logistic regression model controlling for gender and ethnicity, daily injection of narcotics [odds ratio (OR) OR 3.22] and Tajik nationality (OR 7.06) were significantly associated with HIV status. Tajik nationality (OR 1.91), history of arrest (OR 2.37), living/working outside Tajikistan in the past 10 years (OR 2.43), and daily injection of narcotics (OR 3.26) were significantly associated with HCV infection whereas being female (OR 0.53) and always using a sterile needle (OR 0.47) were inversely associated with HCV infection. Among 20 HIV-1-positive IDU with specimens available for typing, 10 were subtype A, 9 were CRF02_AG, and one was an A-CRF02_AG recombinant. Epidemics of HIV-1, HCV, and drug use are underway in Dushanbe. The molecular epidemiology is distinctive, with West African variants accounting for roughly 50% of prevalent infections. Targeted prevention programs offering both needle exchange programs and opiate substitution therapies are urgently called for to prevent the further spread of HIV and HCV in Tajikistan.
Beyrer
Chris
C
Johns Hopkins Bloomberg School of Public Health, Department of Epidemiology, Baltimore, Maryland 21205, USA. cbeyrer@jhsph.edu
Patel
Zeenat
Z
Stachowiak
Julie A
JA
Tishkova
Farida K
FK
Stibich
Mark A
MA
Eyzaguirre
Lindsay M
LM
Carr
Jean K
JK
Mogilnii
Vladimir
V
Peryshkina
Alena
A
Latypov
Alisher
A
Strathdee
Steffanie A
SA
D000328:Adult; D015897:Comorbidity; D003430:Cross-Sectional Studies; D005260:Female; D005838:Genotype; D015483:HIV Antibodies / Q000097:blood; D015658:HIV Infections / Q000453:epidemiology* / Q000821:virology*; D015497:HIV-1 / Q000145:classification / Q000235:genetics / Q000302:isolation & purification; D016174:Hepacivirus / Q000302:isolation & purification; D006526:Hepatitis C / Q000453:epidemiology* / Q000821:virology*; D018937:Hepatitis C Antibodies / Q000097:blood; D006801:Humans; D008297:Male; D017720:Molecular Epidemiology; D012367:RNA, Viral / Q000235:genetics; D012307:Risk Factors; D016036:Seroepidemiologic Studies; D015819:Substance Abuse, Intravenous / Q000150:complications*; D013587:Syphilis / Q000453:epidemiology; D013620:Tajikistan / Q000453:epidemiology; D055815:Young Adult
D015483:HIV Antibodies; D018937:Hepatitis C Antibodies; D012367:RNA, Viral
Lancet. 1997 Jun 21;349(9068):1797-800
9269214
Drug Alcohol Depend. 2000 Apr 1;59(1):17-31
10706972
J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):19-23
17514018
AIDS. 1999 May 7;13(7):741-9
10357372
Am J Trop Med Hyg. 2005 Apr;72(4):495-500
15827294
Lancet. 2003 Oct 11;362(9391):1206
14570036
Addiction. 1999 Sep;94(9):1323-36
10615718
Drug Alcohol Depend. 2006 Apr;82 Suppl 1:S15-22
16769440
JAMA. 2003 Mar 12;289(10):1303-5
12633193
Subst Use Misuse. 1998 Apr;33(5):1231-48
9660649
J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):570-5
16044009
Drug Alcohol Depend. 2006 Apr;82 Suppl 1:S7-14
16769449
AIDS Res Hum Retroviruses. 2004 Oct;20(10):1134-6
15585106
Addiction. 2005 Feb;100(2):150-8
15679744
AIDS. 2000 Jan 7;14(1):75-83
10714570
AIDS Res Hum Retroviruses. 1998 May 20;14(8):669-76
9618078
AIDS. 2004 Nov 19;18(17):2295-303
15577542